Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Game Creek Capital increased its stake in Regeneron by 60.2%, adding 1,850 shares to hold 4,925 shares valued at about $2.77 million at the end of the quarter.
• Regeneron beat quarterly estimates with EPS of $11.44 versus $10.74 and revenue of $3.88 billion versus $3.76 billion, trading with a market cap near $78.8 billion and an average analyst target of $802.27 (Moderate Buy).
• The company raised its quarterly dividend to $0.94 ($3.76 annualized, ~0.5% yield), while insiders have sold 5,274 shares (~$4.14 million) over the past 90 days; insiders now own 7.02% of the stock.

Game Creek Capital LP boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 60.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,925 shares of the biopharmaceutical company's stock after acquiring an additional 1,850 shares during the period. Game Creek Capital LP's holdings in Regeneron Pharmaceuticals were worth $2,769,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $31,000. Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Traub Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $38,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 35 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $745.77 on Friday. The company's 50 day moving average price is $769.73 and its two-hundred day moving average price is $694.17. The firm has a market capitalization of $78.84 billion, a P/E ratio of 17.94, a P/E/G ratio of 2.01 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business earned $12.07 earnings per share. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business's stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Bank of America upgraded shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and boosted their target price for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Evercore lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an "outperform" rating in a research note on Thursday, January 22nd. Canaccord Genuity Group boosted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a "buy" rating in a research report on Thursday, December 4th. Guggenheim upped their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Finally, Zacks Research downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.